Treatment with Bifidobacterium longum plus fructooligosaccharides (Fos) reduced HOMA-IR and NASH activity in association with reduced endotoxin, C-reactive protein, and TNF-α levels [19]. The gene discussed is CRP; the disease is metabolic dysfunction-associated steatohepatitis.